Research programme: cancer diagnostics and therapeutics - Cellectar Biosciences

Drug Profile

Research programme: cancer diagnostics and therapeutics - Cellectar Biosciences

Alternative Names: 127I-CLR 1404; CLR 125; CLR 1401-boron-dipyrromethene analog; CLR 1404; CLR 1500 compounds - Cellectar Biosciences; CLR 1502; CLR 1601 PTX; CLR 1602; CLR 1602-PTX; CLR 1603; CLR 1603-PTX; CLR 1605-GEM; CLR CTX; CLR1401; CLR1501; CLR1505; COLD; GLOW1; GLOW2; PDCs - Cellectar Biosciences; Phospholipid drug conjugates - Cellectar Biosciences; Phospholipid ether analogues - Cellectar Biosciences; PLEs - Cellectar Biosciences

Latest Information Update: 04 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Michigan Medical School
  • Developer Cellectar Biosciences
  • Class Drug conjugates; Imaging agents; Phospholipids; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Apoptosis modulators; CD244 antigen modulators; CD8 positive T lymphocyte modulators; Cell division modulators; DNA synthesis inhibitors; Gene modulators; Histone deacetylase inhibitors; Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Solid tumours

Most Recent Events

  • 01 Aug 2017 Cellectar Biosciences entered into a collaborative agreement with Avicenna Oncology for the development of phospholipid drug conjugates
  • 27 Apr 2017 Pharmacodynamics data from a preclinical study in Solid tumours released by Cellectar Biosciences
  • 25 Apr 2017 Cellectar Biosciences has patent protection for method of use for CLR 1501, CLR 1502 and an additional CLR 1401-boron-dipyrromethene analog in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top